Rock Creek Advisors is contacting you regarding the sale of the SY-2101 program of Syros Pharmaceuticals, Inc. (the “Company” or “Syros”). Assets for sale include:
- Phase 3-ready clinical data package,
- Final FDA/EMA-aligned Phase 3 protocol along with draft briefing book and protocol for a streamlined Phase 3 approach,
- An engaged global network of well-known KOLs,
- Robust API supply,
- Strong commercial CMO relationships,
- Issued patents, and
- US/EU orphan drug designations.
Syros Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline that includes three clinical-stage assets: SY-2101, SY-5609 and tamibarotene.
SY-2101 Overview
SY-2101, a novel, oral formulation of arsenic trioxide (ATO), offers a unique opportunity to build off the established efficacy of intravenously administered ATO in newly diagnosed acute promyelocytic leukemia (APL) while significantly improving the lives of patients by reducing treatment burden of the IV ATO regimen, which involves up to 140 infusions over a typical 10-month course.
Key Strengths
If approved, SY-2101 could become the new standard of care for APL treatment, potentially expanding into other malignancies where ATO has shown promise. Key attributes include:
- Phase 3-Ready Asset: FDA- and EMA-aligned path to approval in frontline APL and potential to leverage Phase 1b data for a streamlined pivotal study. The trial assessed a Phase 3 dose, food effect, and safety of extended administration
- Orphan Drug Designation: Granted in US and EU, providing meaningful exclusivity periods
- Novel Oral Formulation: Of an approved, efficacious drug in APL with potential to replace standard of care by addressing remaining unmet need
- Encouraging PK Cross-Over Data: Demonstrating oral bioavailability >90% and similar exposures between SY-2101 and IV ATO
- Efficient Path to Approval: Comparable oral exposures to IV exposures in the Phase 1b study supports the potential for a smaller, more efficient path to approval
See Teaser linked below for information on the asset’s strengths, clinical information, and phase 3 readiness.
Final Term Sheet Deadline: Friday, January 31st, 2025, 5pm ET
While the Company may give preference to all-cash bids, Rock Creek will consider all types of consideration.
We require an executed Confidentiality Agreement (see NDA link below) and satisfactory evidence of financial wherewithal to provide access to a Confidential electronic data room with more Company information.
If there is another person at your firm who would be more appropriate to review this matter, please let us know and/or forward this information accordingly. Also, if your firm is not interested in pursuing this opportunity, we’d appreciate knowing in order not to continue to follow up with you.